Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study

Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study

Relapsed/refractory multiple myeloma (RRMM) is known to have a high burden of disease and complications associated with refractoriness to prior lines of therapy. Severe pain and fatigue symptoms and impairments in physical and emotional functioning have been strongly linked to reduced health-related...

Full description

Bibliographic Details
Main Authors: Alegre, A. (Author), Bakker, N.A (Author), Bladé, J. (Author), Cavo, M. (Author), Larocca, A. (Author), Laubach, J. (Author), Leleu, X. (Author), Maisel, C. (Author), Mateos, M.-V (Author), Mazumder, A. (Author), Nadeem, O. (Author), Oriol, A. (Author), Orre, M. (Author), Paner, A. (Author), Raptis, A. (Author), Richardson, P.G (Author), Rodriguez-Otero, P. (Author), Sandberg, A. (Author), Torrång, A. (Author), Touzeau, C. (Author)
Format: Article
Language:English
Published: John Wiley and Sons Inc 2022
Subjects:
aged
Aged
Aged, 80 and over
antineoplastic agent
Antineoplastic Combined Chemotherapy Protocols
Biomarkers, Tumor
cancer grading
cancer staging
clinical trial
dexamethasone
Dexamethasone
female
Female
human
Humans
male
Male
melphalan
Melphalan
middle aged
Middle Aged
multiple myeloma
Multiple Myeloma
Neoplasm Grading
Neoplasm Staging
Patient Reported Outcome Measures
patient-reported outcome
phase 2 clinical trial
treatment outcome
Treatment Outcome
tumor marker
very elderly
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items